According to CRISPR Therapeutics's latest financial reports the company's current EPS (TTM) is -5,05ย โฌ. In 2022 the company made an earnings per share (EPS) of -7,97ย โฌ a decrease over its 2021 EPS that were of 4,75ย โฌ.